-- Genetic tumor microenvironment (TME) signature identified as highly predictive of duration of response to cytokine-induced memory-like (CIML) NK cell therapy – -- WU-NK-101 exhibited enhanced anti-tumor activity, robust bone…
Read MoreSAINT LOUIS, MO and SAN DIEGO, CA, November 10, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of…
Read More-- WU-NK-101’s differentiated memory natural killer (NK) expression profile supports enhanced anti-tumor activity and metabolic flexibility -- -- Data support clinical development of WU-NK-101 as monotherapy and in combination with…
Read MoreSAINT LOUIS, MO and SAN DIEGO, CA, November 3, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of…
Read MoreSAINT LOUIS, MO and SAN DIEGO, CA, September 23, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of…
Read More-- WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic function -- -- WU-NK-101 demonstrated robust anti-tumor activity, tumor trafficking, and…
Read MoreCell therapy veteran Natalie Mount, Ph.D., brings more than 25 years of industry experience ST. LOUIS, MO and SAN DIEGO, CA, August 25, 2022- Wugen, Inc., a clinical-stage biotechnology company…
Read MoreST. LOUIS, MO and SAN DIEGO, CA, July 19, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological…
Read More-- WU-NK-101 exhibited enhanced metabolic flexibility and resistance to tumor microenvironment immunosuppression relative to conventional natural killer (NK) cells -- -- WU-NK-101 demonstrated robust anti-tumor activity in vitro and in…
Read MoreST. LOUIS, MO and SAN DIEGO, CA, June 1, 2022- Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and…
Read MoreCopyright © 2025 Wugen. All Rights Reserved.
Privacy Notice
a COGNEO design